SDS Optic will debut on March 15 on the NewConnect market

On Tuesday, March 15, 2022, the first listing of SDS Optic S.A. shares took place. on the NewConnect market. - a company developing the proprietary technology platform inPROBE for real-time medical diagnostics in cancer, infectious, viral, bacterial and fungal diseases. A total of 5,026,250 series A, B and D shares will be introduced to trading.

- The debut on the NewConnect market is ahead of us, which is the culmination of the last year of our work and involvement in various areas of the Company's operations. We hope that the presence on the stock exchange will support the Company's further development plans, including the planned foreign expansion, and will allow it to reach new business partners. We also believe that the Company will gain a wide group of new investors who will see its potential and advantages - says Marcin Staniszewski, president of the board of SDS Optic S.A.

The company intends to gather in one place (as part of the medtech-bio powerhouse) selected innovative scientific projects related to the use of photonic and optoelectronic solutions in medicine at various stages of their advancement. The company assumes the possibility of taking over (in the form of capital involvement) such solutions, obtaining financing for their development and their direct or indirect commercialization in the corporate partnership formula.

Our privacy policy
%d bloggers like this: